Ligand Pharmaceuticals Ratios and Metrics

Market cap in millions SGD. Fiscal year is January - December.

Millions SGD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '25 Aug 11, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Market Capitalization	68	76	-	-	-
Enterprise Value	73	95	-	-	-
Last Close Price	0.17	0.18	-	-	-
PE Ratio	13.88	17.23	-	-	-
PS Ratio	1.27	1.43	-	-	-
PB Ratio	3.03	3.41	-	-	-
P/TBV Ratio	3.36	3.78	-	-	-
P/FCF Ratio	4.90	5.51	-	-	-
P/OCF Ratio	3.29	3.70	-	-	-
EV/Sales Ratio	1.38	1.79	-	-	-
EV/EBITDA Ratio	4.05	7.93	-	-	-
EV/EBIT Ratio	8.93	11.59	-	-	-
EV/FCF Ratio	5.33	6.91	-	-	-
Debt / Equity Ratio	1.02	1.02	2.85	2.43	-4.35
Debt / EBITDA Ratio	1.26	1.26	2.40	1.18	-
Debt / FCF Ratio	1.65	1.65	-	1.79	-
Asset Turnover	1.15	1.15	0.89	1.40	-
Inventory Turnover	25.99	25.99	33.57	51.77	-
Quick Ratio	1.16	1.16	0.30	0.57	0.18
Current Ratio	1.26	1.26	0.36	0.68	0.20
Return on Equity (ROE)	36.54%	36.54%	56.32%	311.50%	-
Return on Assets (ROA)	11.07%	11.07%	9.79%	22.38%	-
Return on Capital (ROIC)	13.46%	13.46%	12.29%	28.87%	-
Return on Capital Employed (ROCE)	22.50%	22.50%	18.00%	48.70%	-
Earnings Yield	6.52%	5.80%	-	-	-
FCF Yield	20.40%	18.15%	-	-	-
Dividend Yield	4.63%	4.15%	-	-	-
Buyback Yield / Dilution	-143.63%	-64.40%	-41.07%	-5.05%	-
Total Shareholder Return	-139.00%	-60.25%	-41.07%	-5.05%	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.